BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 19, 2026
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld

BioWorld
BioWorld RSS Feed RSS

IPO, coins, upward arrow
Med-tech IPO performance 2025

IPO window reopens, med-tech class of 2025 gains 26%

Feb. 12, 2026
By Amanda Lanier
No Comments
After a prolonged downturn, the med-tech IPO market rebounded in 2025, with deal value surging to $13.01 billion across 31 offerings. The recovery followed two muted years, with just $619 million raised in 2024 and a low-point of $110 million in 2023.
Read More
Gold dollar sign and gray question marks

Investors raise concerns on 2026 financing for early stage med tech

Feb. 12, 2026
By Shani Alexander
No Comments
Med-tech companies looking for capital will have to work harder this year to attract investor attention. Even though investment firms have money to deploy, the capital will go toward more targeted opportunities and later-stage companies. For early stage med tech, 2026 is expected to be a tough year, which is raising concerns about the pipeline of innovative technologies in the long term.
Read More
Lab mouse

Human-relevant models lining up to replace animal tests

Feb. 12, 2026
By Nuala Moran
No Comments
The pressure to replace animal testing with human-relevant assays that are more predictive of human-drug responses has now reached a tipping point, and there is a movement toward greater acceptance of these potentially more translatable tests.
Read More
Interleukin 17 (IL-17)
Newco news

Quantx raises $85M to advance oral immunology drugs

Feb. 12, 2026
By Tamra Sami
No Comments
After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor.
Read More
Pills and bottle

Viking to push oral GLP-1/GIP drug into phase III obesity trial

Feb. 12, 2026
By Marian (YoonJee) Chu
No Comments

Viking Therapeutics Inc. said after-market hours Feb. 11 that it plans to advance its oral dual GLP-1/GIP receptor, VK-2735, into a phase III trial for obesity in the third quarter of 2026. VK-2735 is a novel dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist.


Read More
Toddler walking with adult

Dwarfism golden gate? Bridgebio’s infigratinib phase III hits

Feb. 12, 2026
By Randy Osborne
No Comments
Bridgebio Pharma Inc. kept the phase III wins coming, this time with positive top-line results from Propel 3, the global phase III pivotal study of oral infigratinib, designed to inhibit FGFR3 signaling in children with achondroplasia.
Read More

Achondroplasia phase III succeeds for Bridgebio

Feb. 12, 2026
No Comments
A preview of the next edition of BioWorld, Feb. 12, 2026
Read More

NIH ends Xarelto arm of stroke trial due to safety, futility

Feb. 11, 2026
No Comments
Citing an increase in safety events and evidence of futility, the U.S. NIH stopped an investigational low-dose rivaroxaban arm of its Comparison of Anticoagulation and Antiplatelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial.
Read More

Madrigal adds siRNA approach to MASH pipeline in $4.4B Ribo deal

Feb. 11, 2026
No Comments
Continuing to build on the successful launch of Rezdiffra (resmetirom), Madrigal Pharmaceuticals Inc. is adding six preclinical-stage siRNA therapies to its metabolic dysfunction-associated steatohepatitis (MASH) pipeline in a deal with Ribo Life Science Co. Ltd. and its subsidiary, Ribocure Pharmaceuticals AB, that could be worth $4.4 billion if all milestones are achieved.
Read More

Other news to note for Feb. 11, 2026

Feb. 11, 2026
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Arthrosi, Avia Vascular, Calla Lily, Cortec, Cumulus, Dynavax, Foghorn, Generation Bio, Merck, Sanofi, Seastar, Shionogi, Sobi, Vygon, Xoma, Yatiri.
Read More
Previous 1 2 … 33 34 35 36 37 38 39 40 41 … 9036 9037 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing